Research Analysts’ Weekly Ratings Updates for ConvaTec Group (CTEC)

Several analysts have recently updated their ratings and price targets for ConvaTec Group (LON: CTEC):

• 5/22/2026 – ConvaTec Group had its price target lowered by JPMorgan Chase & Co. from GBX 307 to GBX 294. They now have an “overweight” rating on the stock.
• 5/18/2026 – ConvaTec Group had its “buy” rating reaffirmed by UBS Group AG. They now have a GBX 375 price target on the stock.
• 5/18/2026 – ConvaTec Group had its price target lowered by Citigroup Inc. from GBX 250 to GBX 230. They now have a “neutral” rating on the stock.
• 5/15/2026 – ConvaTec Group had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a GBX 325 price target on the stock.
• 4/21/2026 – ConvaTec Group had its “buy” rating reaffirmed by Berenberg Bank. They now have a GBX 340 price target on the stock.
• 4/10/2026 – ConvaTec Group had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a GBX 325 price target on the stock.
• 4/8/2026 – ConvaTec Group had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a GBX 315 price target on the stock.

Insiders Place Their Bets

In other ConvaTec Group news, insider Jonny Mason sold 291,149 shares of ConvaTec Group stock in a transaction dated Monday, March 16th. The stock was sold at an average price of GBX 234, for a total transaction of £681,288.66. Corporate insiders own 0.95% of the company’s stock.

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.